Skip to main content
. 2020 Feb 12;12(2):429. doi: 10.3390/cancers12020429

Figure 5.

Figure 5

Overexpression of wild-type or mutant ABCG2 confers resistance to MLN4924. (A) ABCG2 wild type (R2) and mutants (G2 and T7) were overexpressed in HEK293 cells. ABCG2 expression was determined by immunoblotting. (B) ABCG2-overexpressing cells are resistant to MLN4924 treatment. Cells were treated with the indicated concentrations of MLN4924 for 72 h. Cell viability was measured by MTT assay. Mean ± SD, n = 3. (C) Induction of p21 and p27 is reduced in wild-type ABCG2-overexpressing cells. Cells were treated with the indicated concentrations of MLN4924 for 24 h. Protein expression was determined by immunoblotting. (D) The ABCG2 inhibitors YHO-13351 and FTC increase the activity of MLN4924 in ABCG2 wild-type and mutant overexpressing cells. Cells were treated with the indicated concentrations of MLN4924 with or without YHO-13351 and FTC for 72 h. Cell viability was determined by MTT assay. Mean ± SD, n = 3.